Grünenthal prohibited the research and manufacture of penicillin by German companies. When the ban was lifted, Grünenthal was the first company to introduce penicillin in the postwar period into the German market. This investment achieved a big financial boost for the company. Chemie Grünenthal synthesized thalidomide in 1954 and acquired a 20-year patent. Soon after obtaining a patent in April 1954, the company started clinical trials, and as early as November 1956, marketed the drug for the treatment of respiratory infections under the trade name Grippex, a combination drug that contained thalidomide, quinine, vitamin C, phenacetin, and acetylsalicylic acid. Researchers at
Mevalonic acid Mevalonic acid Mevalonic acid (MVA) is a key organic compound in biochemistry; the name is a contraction of dihydroxymethylvalerolactone. The carboxylate anion of mevalonic acid, which is the predominant form in biological environments, is known as "mevalonate" and is of major pharmaceutical importance. Drugs like statins (which lower levels of cholesterol) stop the production of mevalonate by inhibiting HMG-CoA reductase. Mevalonic acid is very soluble in water and polar organic solvents. It exists in equilibrium with its lactone form, called mevalonolactone, that is formed by internal condensation of its terminal alcohol and carboxylic acid functional groups. Mevalonic acid is a